VOR vs. TERN, TSHA, ATAI, ANNX, PHAT, ESPR, CMRX, ACB, TRML, and MBX
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Terns Pharmaceuticals (TERN), Taysha Gene Therapies (TSHA), Atai Life Sciences (ATAI), Annexon (ANNX), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), Chimerix (CMRX), Aurora Cannabis (ACB), Tourmaline Bio (TRML), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs.
Terns Pharmaceuticals (NASDAQ:TERN) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Terns Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of -0.45, indicating that its share price is 145% less volatile than the S&P 500.
Vor Biopharma's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.
Terns Pharmaceuticals currently has a consensus target price of $18.30, suggesting a potential upside of 350.74%. Vor Biopharma has a consensus target price of $11.36, suggesting a potential upside of 728.99%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Terns Pharmaceuticals.
Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Vor Biopharma had 3 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for Vor Biopharma and 1 mentions for Terns Pharmaceuticals. Vor Biopharma's average media sentiment score of -0.25 beat Terns Pharmaceuticals' score of -0.55 indicating that Vor Biopharma is being referred to more favorably in the news media.
Vor Biopharma received 10 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 69.33% of users gave Vor Biopharma an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote.
Summary
Vor Biopharma beats Terns Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 2/17/2025 by MarketBeat.com Staff